Context Therapeutics Inc. Common Stock (CNTX) Stock Price

CNTXStock
$0.4447.88%52W
Market Cap$40.00M
P/E
PEG Ratio
Div yield
Beta1.75

CNTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-91.19%
Price vs S&P 500 (4W)-24.25%
VGM Score12.83

CNTX Earnings Surprise History

Q2 25-0.09est. -0.05
Q3 25-0.10est. -0.09
Q4 25-0.14est. -0.11
Q1 26-0.09est. -0.12
Q2 26-0.15est. -0.09

CNTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.20
4.19
4.19

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CNTXContext Therapeutics Inc. Common Stock
F$0.44
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Context Therapeutics Inc. Common Stock

Context Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies for solid tumors, with an initial focus on hormone-dependent cancers in women, including breast, ovarian, and endometrial cancer. Its lead program, CTIM-76, is a bispecific antibody that redirects T-cells to attack cancer cells expressing CLDN6, combining immune activation with tumor-specific targeting. The company aims to deliver efficacy while minimizing off-target effects through this precision approach.